每日一次奥西洛司他时辰治疗改善库欣综合征患者的皮质醇节律、生活质量和睡眠
这项前瞻性多中心研究评估了16例生化控制良好的库欣综合征患者,由每日两次奥西洛司他转换为19:00±1小时单次等效剂量后60至90天,唾液皮质醇下午至清晨暴露显著下降,生活质量和睡眠改善,未出现肾上腺功能不全、肝毒性或疾病失控。
要点
- 库欣综合征患者由每日两次奥西洛司他转换为19:00±1小时单次等效剂量后,下午至清晨唾液皮质醇暴露显著下降。
- 转换后生活质量(CushingQoL +4.2,P = .029)和睡眠(匹兹堡睡眠质量指数 -1.7,P = .049)改善。
- 未出现肾上腺功能不全、肝毒性、心电图异常或疾病失控。
核心结论
- 每日一次奥西洛司他可有效且安全地治疗生化控制良好的库欣综合征患者,改善皮质醇昼夜节律、生活质量和睡眠,研究结果支持进一步探索库欣综合征的时辰治疗策略。
研究设计与样本
- 前瞻性多中心研究,纳入16例(4例男性;7例垂体来源)生化控制良好且稳定接受每日两次奥西洛司他的库欣综合征患者,平均年龄53.3 ± 11.8岁。
- 患者在转换为19:00 ± 1小时单次等效每日剂量前及转换后60至90天进行评估。
- 采用超高效液相色谱-串联质谱法对唾液、血清和尿液进行昼夜类固醇分析。
- 评估还包括心血管代谢标志物、生活质量、睡眠功能及安全性结局。
主要发现
- 基线时库欣综合征控制良好,平均奥西洛司他剂量为4.2 ± 1.3 mg。
- 转换后下午至清晨时段唾液皮质醇暴露显著下降(AUC16:00-08:00:-6.1 [-0.15 至 -12.1] ng/mL/h,P = .029)。
- 生活质量和睡眠改善(CushingQoL:+4.2,P = .029;匹兹堡睡眠质量指数:-1.7,P = .049)。
- 血清类固醇前体包括11-脱氧皮质酮(-3.1 ng/mL/h,P = .008)和11-脱氧皮质醇(-17.8 ng/mL/h,P = .005)下降。
- 8例将给药时间提前至16:00 ± 1小时的患者显示可比拟的下降,并出现峰值时间和谷值时间的相位偏移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Medical therapy for Cushing syndrome (CS) typically aims to reduce daily cortisol output without addressing circadian rhythm restoration. No licensed drugs target this goal. OBJECTIVE: We investigated the efficacy and safety of timed, once-daily osilodrostat administration in improving circadian cortisol profiles in CS. METHODS: A prospective, multicenter study evaluated patients with well-controlled CS on a stable twice-daily osilodrostat therapy before and 60 to 90 days after transitioning to a single equivalent daily dose at 19:00 ± 1 hour. Circadian steroid analysis was performed on saliva, serum, and urine using ultra-high performance liquid chromatography-tandem mass spectrometry. Additional assessments included cardio-metabolic markers, quality of life, sleep function, and safety outcomes. RESULTS: Sixteen patients (4 males; 7 pituitary, mean age 53.3 ± 11.8 years) were enrolled. At baseline, CS was well-controlled with a mean osilodrostat dose of 4.2 ± 1.3 mg. After transitioning, salivary cortisol exposure decreased significantly during the afternoon to early morning period (AUC16:00-08:00: -6.1 [-0.15 to -12.1] ng/mL/h, P = .029). Quality of life and sleep improved (CushingQoL: +4.2, P = .029; Pittsburgh Sleep Quality Index: -1.7, P = .049). Serum steroid precursors, including 11-deoxycorticosterone (-3.1 ng/mL/h, P = .008) and 11-deoxycortisol (-17.8 ng/mL/h, P = .005), decreased. Eight patients advancing dosing to 16:00 ± 1 hour showed comparable reductions, with phase shifts in acrophase and nadir. No patients developed adrenal insufficiency, liver toxicity, electrocardiogram abnormalities, or loss of disease control. CONCLUSION: Once-daily osilodrostat effectively and safely treats patients with biochemically controlled CS, improving circadian cortisol profiles, quality of life, and sleep. Findings support further exploration of chronotherapy-based approaches in CS management.
引用
- Ferrari D, Bonaventura I, Simeoli C, et al. Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome. J Clin Endocrinol Metab. 2025. PMID: 40172910. doi:10.1210/clinem/dgaf206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。